drugset / Trial / NCT06617715
Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday). The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13.
Timeline
- Start
- 2024-10-23
- Primary completion
- 2026-05-12
- Completion
- 2026-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Prevnar 13 | Vaccine | 0.5 ml | Intramuscular |
| Subject | Sinovac PCV13 | Vaccine | 0.5 ml | Intramuscular |